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Recently, the Association for Molecular Pathology (AMP),
the American Society of Clinical Oncology (ASCO), and the
College of American Pathologists (CAP) published consensus
guidelines in The Journal of Molecular Diagnostics to stan-
dardize variant interpretation and reporting in oncology
specimens.1 This group’s recommendations included guid-
ance related to a dilemma commonly encountered in clinical
practicedaccurately distinguishing somatic mutations that
arose in a patient’s tumor from inherited germline variants.
Distinguishing somatic from germline variants is impor-
tant for several reasons. First, most germline sequence
variants will be clinically benign, and these should not be
included in clinical reports of actionable somatic driver
mutations. Second, however, some rare germline variants
are pathogenic and may be associated with an inherited
disorder, including familial cancer predisposition. It is
important to recognize these variants as inherited to ensure
appropriate management not only of the patient but also of
family members. Moreover, even when germline variants
are not associated with a high-penetrance cancer suscepti-
bility syndrome, they may be functionally and even
clinically significant. Finally, accurately recognizing that a
sequence variant is of somatic origin may provide evidence
of a clonal process, which can be diagnostically important in
some neoplastic conditions, such as myeloid neoplasia.2
The task of distinguishing somatic and germline variants
is made more difficult in tumor-only sequencing protocols.
These workflows involve identification of mutations in
neoplastic tissue without comparison to a normal sample
from the patient. Many clinical laboratories have adoptedsuch protocols for practical reasons and/or to avoid the
substantial cost of sequencing paired normal specimens.
However, tumor-only workflows carry some risk of
misclassifying somatic and germline variants.
The ASCO/AMP/CAP guidelines make several recom-
mendations to assist recognition of germline variants in
tumor-only protocols.1 Chief among these, the guidelines
indicate that the main criterion for germline designation is
variant allele fraction (VAF), which the authors note is
expected to be near 50% or 100% for heterozygous and
homozygous germline alleles, respectively, that are present
at diploid copy number in all cells in a specimen. However,
performance metrics of this recommendation have not been
established. Moreover, as the authors of the guidelines
acknowledge, there are certain limitations to using VAF as a
screen for germline variants. For instance, somatic muta-
tions may also be present near 50% or 100% VAF in tissue
with high tumor burden, and germline variants may deviate
from 50% or 100% VAF because of chromosomal aneu-
ploidy or other changes in gene copy number, both of which
are common in tumors.
We examined the usefulness of the AMP/ASCO/CAP
guideline for identification of germline variants in a cohort
of 1310 cancer patients with paired sequencing of >200
genes in both a tumor and a normal sample (peripheral
blood or tissue) as part of a large next-generation
sequencing research program at our institution
(LCCC1108/UNCSeq, NCT01457196).3 A diverse group of
neoplasms was represented in this cohort. Common sites of
tumor origin included gynecologic tract (n Z 402), breast
(n Z 212), head and neck (n Z 203), gastrointestinal tract
organs (n Z 115), nervous system/brain (n Z 95),
Figure 1 Density plots of allele fraction for germline variants in tumor
and paired normal samples. Density plots are shown for the observed allele
fraction of germline variants measured in tumor and paired normal samples
from 1310 subjects. Light gray regions represent the area encompassed
under both curves. For this analysis, variants detected in the paired normal
sample were defined as germline variants. However, to be included in the
study, variants were required to have a read depth of 100 in both tumor
and normal samples. Approximately 6.8 million variants met these inclusion
criteria. Somatic variants present only in the tumor sample are not included
in this plot. VAF, variant allele fraction.
Figure 2 Comparison of variant allele fraction (VAF) of germline 
variants in tumor and paired normal samples. Observed VAF for germline 
variants in normal samples (x axis) and tumor samples (y axis). Results from 
a random sample of 100,000 variants (of 6.8 million total variants) are 
plotted for visualization. Among variants at 40% to 60% VAF in the normal 
sample, 78% are also detected at 40% to 60% VAF in tumor (boxed area), 
10% were detected at >60% VAF in tumor (top dashed boxed area), and 
11% were detected at <40% VAF in tumor (bottom dashed boxed area).genitourinary system (n Z 94), hematologic/lymphoid
(n Z 57), soft tissue (n Z 46), skin (n Z 30), and lung
(n Z 28).
Analysis was restricted to regions with 100 or deeper
coverage in both the tumor and normal samples. Within
these regions, a total of 6.8 million variants were identified
in the normal samples as candidate germline variants.
Density plots of observed VAFs for these variants are
shown in Figure 1. As expected, measured VAF of germline
variants in normal tissue showed a bimodal distribution,
with peaks centered at 50% and 100%. Although a bimodal
pattern was also observed for germline variants in tumor
samples, the Gaussian distribution was broader around the
50% VAF peak, indicating a wider range of VAFs for these
variants within the tumor samples (Figure 1).
To further explore this observation, VAFs of variants
detected in normal samples were plotted against VAFs of
the same variants in tumor samples (tumor VAF)
(Figure 2). As expected, germline variants were densest in
both normal and tumor VAFs at around 50% and 100%. In
the tumor sample, 46% of all germline variants were
present at VAFs between 40% and 60%, as expected for a
heterozygous allele, and 35% of all germline variants were
present at a VAF of >95%. However, 19% of candidate
germline variants exhibited a VAF in the tumor sample
outside of the ranges suggested by the AMP/ASCO/CAP
guidelines. This deviation was particularly striking for
heterozygous germline variants, many of which showed
considerable scatter away from 50% VAF in the tumor
sample (Figure 2). Specifically, 22% of germline variants
that were detected at a VAF between 40% and 60% in the
normal sample (representing heterozygous alleles) had aVAF outside of this range in the paired tumor samples
(10% with a VAF of >60% and 11% with a VAF of
<40%) (Figure 2).
Next, the percentage of all variants with a tumor VAF
between 40% and 60% that were germline versus somatic in
origin was determined. Of a total of 3.1 million variants
with a tumor VAF between 40% and 60%, most (96%) were
confirmed as germline by presence in the normal sample
(data not shown).
Our observations indicate that the VAF of a substantial
percentage of germline variants will deviate markedly from
50% or 100% in tumor samples. Although performance
metrics are likely to be affected by several variables,
including tumor type and tumor percentage, these data
provide an informative first estimate of the sensitivity and
specificity of the AMP/ASCO/CAP guideline for identifica-
tion of germline variants in a cohort of patients with diverse
tumors. As such, our observations have important implica-
tions for variant interpretation in tumor-only platforms.
In our cohort, VAF discordance between normal and tumor
samples was most prominent for heterozygous alleles. In a
subset of these cases, the finding of a VAF of<40% or>60%
in tumor may indicate loss of heterozygosity of a pathogenic
germline variant, a possibility worthy of future study.
However, given that such discordance was common in our
cohort, it may be more often the case that changes in VAF in
tumor are passenger effects of an unstable genome.
Ultimately, there is no true substitute to tumor-normal
pairs in the accurate distinction of germline from somatic
variants. However, given persistent reimbursement issues in
this space,4 the additional expense of paired normal
sequencing may prove cost prohibitive for many labora-
tories. Although the AMP/ASCO/CAP recommendations
provide helpful guidance to such laboratories, reporting
should emphasize the inherent inability of definitively dis-
tinguishing germline and somatic variants in tumor-only
sequencing assays. If suspicion for a germline-inherited
variant is present, follow-up testing of a normal sample
should be recommended.References
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